USD 10.0
(19.47%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 27.84 Million SGD | -4.64% |
2022 | 29.2 Million SGD | 3732.02% |
2021 | 762 Thousand SGD | -14.57% |
2020 | 892 Thousand SGD | -89.82% |
2019 | 8.76 Million SGD | -62.32% |
2018 | 23.25 Million SGD | -48.39% |
2017 | 45.04 Million SGD | -1.64% |
2016 | 45.79 Million SGD | 5.17% |
2015 | 43.54 Million SGD | -22.7% |
2014 | 56.33 Million SGD | 136.85% |
2013 | 23.78 Million SGD | 3.28% |
2012 | 23.02 Million SGD | 85.6% |
2011 | 12.4 Million SGD | 0.0% |
2010 | - SGD | 0.0% |
2009 | - SGD | 0.0% |
2008 | - SGD | 0.0% |
2007 | - SGD | 0.0% |
2006 | - SGD | -100.0% |
2005 | 105 Thousand SGD | -97.79% |
2004 | 4.75 Million SGD | -95.14% |
2003 | 97.83 Million SGD | -31.4% |
2002 | 142.62 Million SGD | -12.5% |
2001 | 162.99 Million SGD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 36.29 Million SGD | 0.0% |
2024 Q1 | 36.29 Million SGD | 30.34% |
2023 FY | 27.84 Million SGD | -4.64% |
2023 Q2 | 28.01 Million SGD | 0.0% |
2023 Q3 | 27.84 Million SGD | -0.59% |
2023 Q1 | 28.01 Million SGD | -4.08% |
2023 Q4 | 27.84 Million SGD | 0.0% |
2022 Q1 | 12.92 Million SGD | 1595.67% |
2022 Q4 | 29.2 Million SGD | 2.45% |
2022 FY | 29.2 Million SGD | 3732.02% |
2022 Q3 | 28.5 Million SGD | 120.58% |
2022 Q2 | 12.92 Million SGD | 0.0% |
2021 Q3 | - SGD | 0.0% |
2021 FY | 762 Thousand SGD | -14.57% |
2021 Q2 | - SGD | 0.0% |
2021 Q4 | 762 Thousand SGD | 0.0% |
2021 Q1 | - SGD | -100.0% |
2020 Q4 | 892 Thousand SGD | 0.0% |
2020 FY | 892 Thousand SGD | -89.82% |
2020 Q2 | - SGD | 0.0% |
2020 Q3 | - SGD | 0.0% |
2020 Q1 | - SGD | -100.0% |
2019 Q4 | 8.76 Million SGD | -63.79% |
2019 Q2 | 23.81 Million SGD | 3.28% |
2019 Q3 | 24.19 Million SGD | 1.59% |
2019 Q1 | 23.06 Million SGD | -0.81% |
2019 FY | 8.76 Million SGD | -62.32% |
2018 Q2 | 23.25 Million SGD | -0.81% |
2018 Q3 | 23.06 Million SGD | -0.81% |
2018 Q4 | 23.25 Million SGD | 0.82% |
2018 Q1 | 23.44 Million SGD | -47.97% |
2018 FY | 23.25 Million SGD | -48.39% |
2017 FY | 45.04 Million SGD | -1.64% |
2017 Q4 | 45.04 Million SGD | 0.0% |
2017 Q3 | 45.04 Million SGD | -4.0% |
2017 Q2 | 46.92 Million SGD | -0.79% |
2017 Q1 | 47.3 Million SGD | 3.28% |
2016 Q1 | 45.79 Million SGD | 5.17% |
2016 Q2 | 48.8 Million SGD | 6.56% |
2016 Q3 | 50.3 Million SGD | 3.08% |
2016 Q4 | 45.79 Million SGD | -8.96% |
2016 FY | 45.79 Million SGD | 5.17% |
2015 Q2 | 55.79 Million SGD | -4.89% |
2015 FY | 43.54 Million SGD | -22.7% |
2015 Q4 | 43.54 Million SGD | -17.32% |
2015 Q3 | 52.67 Million SGD | -5.59% |
2015 Q1 | 58.65 Million SGD | 4.13% |
2014 FY | 56.33 Million SGD | 136.85% |
2014 Q1 | 57.94 Million SGD | 143.62% |
2014 Q4 | 56.33 Million SGD | 29.74% |
2014 Q3 | 43.41 Million SGD | -15.96% |
2014 Q2 | 51.66 Million SGD | -10.84% |
2013 Q2 | 24.1 Million SGD | 1.92% |
2013 Q1 | 23.65 Million SGD | 2.71% |
2013 Q4 | 23.78 Million SGD | 0.56% |
2013 Q3 | 23.65 Million SGD | -1.88% |
2013 FY | 23.78 Million SGD | 3.28% |
2012 FY | 23.02 Million SGD | 85.6% |
2012 Q1 | 17.99 Million SGD | 45.02% |
2012 Q2 | 18.05 Million SGD | 0.32% |
2012 Q3 | 23.1 Million SGD | 28.0% |
2012 Q4 | 23.02 Million SGD | -0.33% |
2011 Q3 | 12.01 Million SGD | 0.0% |
2011 Q1 | - SGD | 0.0% |
2011 Q2 | - SGD | 0.0% |
2011 Q4 | 12.4 Million SGD | 3.31% |
2011 FY | 12.4 Million SGD | 0.0% |
2010 Q1 | - SGD | 0.0% |
2010 Q3 | - SGD | 0.0% |
2010 Q2 | - SGD | 0.0% |
2010 FY | - SGD | 0.0% |
2010 Q4 | - SGD | 0.0% |
2009 FY | - SGD | 0.0% |
2009 Q4 | - SGD | 0.0% |
2008 FY | - SGD | 0.0% |
2007 FY | - SGD | 0.0% |
2006 FY | - SGD | -100.0% |
2005 FY | 105 Thousand SGD | -97.79% |
2004 FY | 4.75 Million SGD | -95.14% |
2003 FY | 97.83 Million SGD | -31.4% |
2002 FY | 142.62 Million SGD | -12.5% |
2002 Q4 | 143.18 Million SGD | 0.0% |
2002 Q2 | 151.2 Million SGD | 0.0% |
2001 FY | 162.99 Million SGD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
AstraZeneca PLC | 28.58 Billion USD | 99.903% |
Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 99.933% |
CSPC Pharmaceutical Group Limited | 99.64 Million USD | 72.055% |
Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | 34.122% |
Novartis AG | 26.34 Billion USD | 99.894% |
PT Kalbe Farma Tbk. | 40.4 Million USD | 31.084% |